Our Milestones
| Date | Milestone |
|---|---|
| June 2002 | Phoenix Eagle Company Pty Ltd founded |
| July 2002 | Provisional patent application filed in Australia |
| July 2003 | PCT (Patent Co-operation Treaty) patent application filed |
| July 2005 | Quadriplegic Centre Report issued –Successful outcomes in the treatment of non-healing pressure ulcers in a Perth hospital from use of OPAL A |
| Apr 2006 | First patent granted – in South Africa – without examination |
| Feb 2008 | First patent granted after examination – in New Zealand (after 4 examinations) |
| May 2008 | Publication of manuscript by Associate Professor Nick Graves of Queensland University of Technology and Dr Elaine Ashby, Senior Medical Consultant of the Taku Group, California, in Wound Practice and Research describing the clinical use of OPAL A in the Quadriplegic Centre, Perth |
| May 2008 | Presentation by Associate Professor Geffrey Mitchell of The University of Queensland School of Medicine at the Australian Wound Management Association Conference in Darwin on OPAL A, entitled “Alkalised fruit extract as a potential treatment for chronic ulcers.” |
| Dec 2008 | Australian patent granted |
| July 2009 | Engagement of Emeritus Professor Keith Brocklehurst and Professor Michael Philpott of Queen Mary College, The University of London to undertake research into the proteolytic activity of the cysteine proteases in OPAL A |
| Feb 2010 | Commencement of a proof-of-concept clinical trial for the use of OPAL A in the treatment of venous and pressure ulcers at the Heidelberg Repatriation Hospital in Melbourne |
| July 2010 | Appointment of Professor Michael Philpott, lead of the Centre for Cutaneous Research at the Blizard Institute in London, to direct and manage an ongoing program of scientific studies into the properties of OPAL A |
| Oct 2010 | Award of a scholarship for a Ph D, supervised by Professor Michael Philpott, to Sreekanth Vootukuri Reddy to investigate the active molecules in OPAL A and their activities |
| Sep 2011 | Professor Geoffrey Mitchell granted Authorised Prescriber status by the TGA for the use of OPAL A as an unapproved therapeutic good to treat non-healing venous and pressure ulcers |
| July 2012 | First U.S. patent issued |
| Nov 2013 | Associate Professor Michael Woodward granted Authorised Prescriber status by the TGA for the use of OPAL A as an unapproved therapeutic good to treat non-healing venous and pressure ulcers |
A number of important milestones relating to the discoveries and inventions made in the course of the work at Queen Mary University of London (as Queen Mary and Westfield College was renamed) have been achieved during the last 5 years, which will be the subject of second generation patent applications. At present this valuable Intellectual Property is Confidential.